

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

CYCLO3PSS CORP
Form 10QSB
October 15, 2001

CONFORMED

U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE QUARTER ENDED AUGUST 31, 2001

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 0-22720

CYCLO3PSS CORPORATION

(Name of Small Business Issuer as specified in its charter)

Delaware

87-0455642

(State or other jurisdiction of
Incorporation or organization)

(I.R.S. Employer
Identification No.)

3646 West 2100 South
Salt Lake City, Utah

84120-1202

(Address of principal executive offices)

(Zip Code)

Issuer's telephone number, including area code: (801) 972-9090

Securities registered pursuant to Section 12(b) of the Exchange Act: None

Securities registered pursuant to Section 12(g) of the Exchange Act: \$.001
Par Value Common Stock

Check whether the Issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes X No .

Common Stock outstanding at October 14, 2001 - 36,851,348 shares of \$.001 par
value Common Stock.

DOCUMENTS INCORPORATED BY REFERENCE: NONE

FORM 10-QSB

Financial Statements and Schedules

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Cyclo3pss Corporation

For Three Months Ended August 31, 2001

The following financial statements and schedules of the registrant and its consolidated subsidiaries are submitted herewith:

PART I - FINANCIAL INFORMATION

	Page of Form 10-QSB
Item 1. Financial Statements	
Condensed Consolidated Balance Sheets3
Condensed Consolidated Statements of Operations5
Condensed Consolidated Statements of Cash Flows7
Notes to Condensed Consolidated Financial Statements8
Item 2. Management's Discussion and Analysis and Plan of Operations	13

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	21
Item 2. Changes in Securities	21
Item 3. Defaults Upon Senior Securities	21
Item 4. Submission of Matters to a Vote of Security Holders	21
Item 5. Other Information	21
Item 6. Exhibits	21

-2-

CYCLO3PSS CORPORATION Condensed Consolidated Balance Sheets (Unaudited)

	August 31 2001	February 28 2001
Assets		
Current assets:		
Cash	\$ 11,446	\$ 62,022
Accounts receivable	18,261	28,850
Notes receivable from OxiDyn	-	80,000
Notes receivable from Paragon, net of allowance of \$251,530	-	-
Prepaid expenses	621	3,462
Total current assets	30,328	174,334
Property and equipment, net	30,861	67,800
Other assets:		
Acquired patents, net	18,207	36,407

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Developed patents and other, net	31,233	36,693
	-----	-----
	\$ 110,629	\$ 315,234
	=====	=====

-3-

CYCLO3PSS CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited) (continued)

	August 31 2001	February 28 2001
Liabilities and stockholders' equity (deficit)		
Current liabilities:		
Accounts payable	\$ 212,590	\$ 124,937
Accrued liabilities	194,157	119,351
Notes payable	658,000	1,000,000
Note payable to officer	-	10,000
Deferred revenue	100,000	100,000
	-----	-----
Total current liabilities	1,164,747	1,354,288
Commitments and contingencies		
Stockholders' deficit:		
Preferred stock:		
Preferred stock issuable in series: par value \$.01, 4,500,000 shares authorized:		
Series "A" convertible preferred stock; 356,638 shares authorized; 356,638 shares issued and outstanding	356	356
Series "B" convertible preferred stock; 30,000 shares authorized; 320 and 614 shares issued and outstanding August 31, and February 28, 2001, respectively	3	6
Series "E" convertible preferred stock; 10,000 shares authorized; 500 shares issued and outstanding	5	-
Common stock, par value \$.001; 55,000,000 shares authorized; 35,326,267 and 30,352,826 shares issued and outstanding at August and February 2001 respectively	35,326	30,353
Additional paid-in capital	20,331,974	19,504,245
Deferred stock-based compensation	-	(1,969)
Stock subscription received	-	190,000
Accumulated deficit	(20,920,237)	(20,260,500)
Less treasury stock, 264,000 common shares at cost	(501,545)	(501,545)
	-----	-----
Total stockholders' equity (deficit)	(1,054,118)	(1,039,054)
	-----	-----
	\$ 110,629	\$ 315,234
	=====	=====

See accompanying notes to condensed consolidated financial statements

-4-

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

CYCLO3PSS CORPORATION Condensed Consolidated Statements of Operations (Unaudited)

	For the three months ended August 31,	
	2001	2000
Net revenues	\$ 24,614	\$ 6,321
Costs and expenses:		
Cost of revenues	60,837	73,932
Research and development	17,772	20,389
Selling and marketing	40,005	35,985
General and administrative	409,080	201,041
Depreciation and amortization	21,453	20,439
	-----	-----
Total expenses	549,147	351,786
Loss from continuing operations	(524,533)	(345,465)
Interest income	1,702	1,684
Interest expense	-	(44)
	-----	-----
Net loss from continuing operations	(522,831)	(343,465)
Discontinued operation:		
Gain on sale of discontinued operations	12,009	-
Loss from discontinued operations	(4,595)	(25,091)
	-----	-----
Net gain (loss) from discontinued operations	7,414	(25,091)
	-----	-----
Net Loss	\$ (515,417)	\$ (368,916)
	=====	=====
Basic and diluted net loss per common share:		
Continued operations	\$ (.01)	\$ (.01)
Discontinued operations	\$ (.00)	\$ (.00)
	-----	-----
Net loss per common shares- basic and diluted	\$ (.01)	\$ (.01)
	=====	=====
Weighted average number of common shares issued and outstanding	34,869,020	27,159,853
	=====	=====

See accompanying notes to condensed consolidated financial statements

-5-

CYCLO3PSS CORPORATION Condensed Consolidated Statements of Operations (Unaudited)

	For the six months ended August 31,	
	2001	2000
Net revenues	\$ 201,278	\$ 82,408
Costs and expenses:		

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Cost of revenues	135,899	125,971
Research and development	24,815	33,845
Selling and marketing	78,161	65,581
General and administrative	609,854	443,725
Depreciation and amortization	42,180	83,158
	-----	-----
Total expenses	890,909	452,280
Loss from continuing operations	(689,631)	(669,875)
Interest income	1,809	2,175
Interest expense	-	(131)
	-----	-----
Net loss from continuing operations	(687,822)	(667,828)
Discontinued operation:		
Gain on sale of discontinued operations	12,009	-
Loss from discontinued operations	16,076	23,943
	-----	-----
Net gain (loss) from discontinued operations	28,085	23,943
	-----	-----
Net Loss	\$ (659,737)	\$ (643,885)
	=====	=====
Basic and diluted net loss per common share:		
Continued operations	\$ (.02)	\$ (.02)
Discontinued operations	\$ (.00)	\$ (.00)
Net loss per common shares- basic and diluted	\$ (.02)	\$ (.02)
	=====	=====
Weighted average number of common shares issued and outstanding	33,946,605	27,236,575
	=====	=====

See accompanying notes to condensed consolidated financial statements

-6-

CYCLO3PSS CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)

For the six months ended
August 31,
2001 2000

Cash flows from operating activities:		
Net loss	\$ (659,737)	\$ (643,885)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	42,180	93,766
Common Stock issued for services	-	177,060
Stock based compensation	1,969	-
Common stock issued for legal settlement	25,000	-
Gain on sale of discontinued operations	(12,009)	-
Write off of note receivable	200,386	-
Changes in assets and liabilities:		
Accounts receivable	10,589	9,238
Prepaid expenses	2,841	(5,120)

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Accounts payable and accrued liabilities	162,459	(435,167)
	-----	-----
Net cash used in operating activities	(226,322)	(804,108)
	-----	-----
Cash flows from investing activities:		
Purchase of property and equipment	(851)	(11,713)
Proceeds from sale of discontinued operations	33,470	-
Increase to notes receivable from OxiDyn	(120,386)	-
Addition to developed patents and other	(2,191)	(31,728)
	-----	-----
Net cash used in investing activities	(89,958)	(43,441)
	-----	-----
Cash flows from financing activities:		
Proceeds from issuance of common stock	100,000	-
Proceeds from issuance of warrants	-	196,000
Proceeds from exercise of stock options	17,704	5,578
Proceeds from issuance of notes payable	158,000	750,000
Payment on note payable from officer	(10,000)	-
Principal payments under capital lease obligations	-	(2,944)
	-----	-----
Net cash provided by financing activities	265,704	948,934
	-----	-----
Net increase (decrease) in cash	(50,576)	101,385
Cash at beginning of period	62,022	107,565
	-----	-----
Cash at end of period	\$ 11,446	\$ 208,950
	=====	=====
Non-cash financing activities:		
Issuance of common stock for stock subscription	190,000	-
Conversion of note payable into preferred stock	\$ 500,000	\$ -
Conversion of preferred stock into common stock	3	2

See accompanying notes to condensed consolidated financial statements.

-7-

CYCLO3PSS CORPORATION

Notes to Condensed Consolidated Financial Statements (Unaudited)

1. Summary of Significant Accounting Policies

Organization

The Corporation was formed in Delaware in 1927. In 1990, the Corporation was reorganized as Cyclo3pss Medical Systems, Inc. In 1995, the Company changed its name to Cyclo3pss Corporation (The Company). The Company is engaged in the manufacture, sale and installation of ozone food processing products, ozone washing for commercial and institutional laundries, and research and development of technologies for the sterilization and/or disinfection of surgical and medical instruments, as well as ozone based consumer appliances.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated.

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

The accompanying unaudited condensed consolidated financial statements are stated in accordance with the instructions to Form 10-QSB and do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.

Operating results for the six months ended August 31, 2001 are not necessarily indicative of the results that may be expected for the full year. The unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-KSB for the year ended February 28, 2001.

Comprehensive Income

Statement of Financial Accounting Standards ("SFAS") No. 130, "Reporting Comprehensive Income", requires that all items that are recognized under accounting standards as components of comprehensive income be reported in a financial statement that is displayed with the same prominence as other financial statements. The items of other comprehensive income that are typically required to be displayed are foreign currency items, minimum pension liability adjustments, and unrealized gains and losses on certain investments in debt and equity securities. There have been no items of other comprehensive income to date.

-8-

CYCLO3PSS CORPORATION

Notes to Condensed Consolidated Financial Statements (Unaudited)

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to previously reported amounts to conform to the current presentation.

Letter of Intent to Acquire OxiDyn, Incorporated

In October 2000, the Company entered into a letter of intent to acquire OxiDyn, Incorporated (OxiDyn), a North Carolina based manufacturer of ozone based clean-in-place and sanitizing rinsing systems for the beverage and bottling industry. A preliminary acquisition agreement was executed in February 2001, subject to final negotiation, which called for the Company to issue shares of common stock determined by dividing OxiDyn's net book value by the average closing price of the Company's common stock during the five-day trading period immediately prior to the closing date of the acquisition.

In November 2000, the Company loaned \$80,000 to OxiDyn to meet its current operating requirements. In order to provide the above funding, the acquisition agreement called for the Company to complete a private placement offering of at least \$300,000 at a price of \$0.195 per share, which was to be purchased by OxiDyn's investors and shareholders. The Company received cash

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

of \$190,000 related to the offering prior to February 28, 2001, which was reported as a stock subscription received in the financial statements. Subsequent to February 28, 2001, the Company completed the private placement offering receiving gross proceeds of \$290,000, including the subscription received, and issued 1,487,179 shares of common stock. The Company advanced an additional \$120,386 in cash to OxiDyn subsequent to February 2001 to meet additional operating requirements.

OxiDyn has been unable to meet various expected operational target milestones over the past twelve months, raising doubt that the proposed acquisition will close. Therefore, the Company wrote off the note receivable and other funds advanced totaling \$200,386 during the three months ended August 31, 2001.

-9-

CYCLO3PSS CORPORATION

Notes to Condensed Consolidated Financial Statements (Unaudited)

Asset purchase and sale agreement with Paragon, LLC

On June 15, 2001, the Company entered into an asset purchase and sale agreement with Paragon, LLC. The Principals of which are the employees of Cyclopss Biochemical Corporation. The purchase price was \$285,000, which was established as the fair value for the Company, and approved by the board of directors. The Company received \$30,000 as a down payment and financed the balance of \$255,000 over five years, at 8% interest, secured by the Paragon's assets.

The terms of the sale agreement allow for a discount in the purchase price of \$50,000 or \$40,000 if all amounts due under the note receivable, less the purchase price discount, are paid prior to September 1, 2001 or December 31, 2001, respectively.

The Company expects to recognize a gain on the sale of the biochemical products business, but due to the extended payment terms on the note receivable, the gain on sale will be recognized as payments are received. The Company received a total of \$33,470 related to the purchase price and through the date of this filing has recorded a gain on sale of discontinued operations of \$12,009.

The biochemical products business has been accounted for as discontinued operations and accordingly, the results of operations are segregated from continuing operations in the accompanying 2001 statements of operations. Revenue, operating costs and expenses, other income and expenses of this business has been reclassified to discontinued operations for the three and six months ended August 31, 2001 and 2000. No allocation of general corporate overhead has been made to discontinued operations relating to this business.

-10-

CYCLO3PSS CORPORATION

Notes to Condensed Consolidated Financial Statements (Unaudited)

2. Basis of Presentation

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has sustained significant net losses which have resulted in an accumulated deficit at August 31, 2001 of \$20,920,237 and \$20,260,500 at February 28, 2001, and periodic cash flow difficulties, and is in default on

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

debt covenants, all of which raise substantial doubt of the Company's ability to continue as a going concern.

The net loss for the year ended February 28, 2001 was \$1,114,855 and the Company recorded a net loss of \$659,737 for the six months ended August 31, 2001. To date, the Company has funded its operations through the issuances of debt and common and preferred stock. The Company anticipates a net loss for the year ended February 28, 2002, and with a cash balance of \$11,446 at August 31, 2001 and expected cash requirements for the year, there is substantial doubt as to the Company's ability to continue operations.

The Company believes that these conditions have resulted from the inherent risks associated with small technology companies. Such risks include, but are not limited to, the ability to: a) generate sales of its product at levels sufficient to cover its costs and provide a return for investors, b) attract additional capital in order to finance growth, c) further develop and successfully market commercial products and d) successfully compete with other technology companies having financial, production and marketing resources significantly greater than those of the Company.

The Company is attempting to improve these conditions by way of financial assistance through collaborative partnering agreements, issuances of additional equity, debt arrangements, and product sales. Management believes that appropriate funding will be generated and future product sales will result from these opportunities and that the Company will continue operations through the next fiscal year; however, no assurance can be given that sales will be generated or that the additional necessary funding will be raised.

-11-

CYCLO3PSS CORPORATION

Notes to Condensed Consolidated Financial Statements (Unaudited)

3. Contingencies

The Company is not a party to and presently is not aware of any pending claims or existing litigation. The Company issued 250,000 shares of common stock during the three months ended August 31, 2001 as final adjustment of a previous legal settlement, for which the Company recorded a non-cash charge of \$25,000. Previous settled matters are described in the Company's Form 10-KSB for the year ended February 28, 2001.

4. Segment Information

On March 7, 2000 the Company internally realigned its ozone businesses, collapsing these separate business units into a single entity. The Company operated in two principal industries; the manufacture, sale and installation of ozone products ("ozone products"); and the manufacture and sale of specialty chemicals ("biochemical products").

On June 15, 2001 the Company sold the assets and business related to its biochemical products (see Note 1). The Company now only operates in one segment.

5. Long term debt

In December 1999, the Company negotiated a letter of intent with a strategic partner that provided for two separate financings. The first, an unsecured promissory note for \$250,000, was executed and funded in concert with the signing of the letter of intent. The second financing is a convertible secured loan for \$750,000 which was funded in the second quarter of fiscal 2001. The loan agreement is collateralized by a first security interest in all of the

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Company's intellectual property and was due and payable in one year from its execution. The loan and accrued interest is convertible, in whole or in part, into the Company's common stock at anytime during the loan term.

In February 2001, the Company renegotiated the loan whereby the unpaid accrued interest on the notes of \$97,397 was converted into 593,777 shares of common stock and \$500,000 of the principal balance would be converted into 500,000 shares of Series "E" convertible preferred stock, which occurred in March 2001. Under the terms of the renegotiated loan agreement, the remaining \$500,000 principal balance is due February 28, 2002.

Under the terms of the loan agreements, the Company is subject to various covenants, including maintaining minimum liquid assets in the form of cash or marketable securities of \$100,000. At February 28, 2001 and subsequent to that date, the Company is in default with the minimum liquid assets covenant and, therefore, the loan may be called at any time.

-12-

PART I - ITEM 2

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

General

Cyclopss Corporation is primarily engaged in ozone application technologies and processes. The Company believes that its technologies and product lines offer cost effective, energy efficient, environmentally benign alternatives for cleaning and disinfection products and systems. We believe that the technologies are easily scalable from consumer appliances up through industrial systems. The products provide systems to address food safety, particularly microbial reductions on meat and poultry, fruits and vegetables. Additional products offered by the Company enable manufacturers to eliminate microbial build up in and on plant equipment, while other ozone-related products are marketed by the Company to commercial and institutional laundry operators enable users to reduce costs associated with labor, water, energy, chemicals, and wastewater disposal. The Company has developed consumer product prototypes ranging from the sanitization of kitchen sponges and toothbrushes, to counter top drinking water processors and food sanitizers.

In October 2000, the Company entered into a letter of intent for acquisition/merger of OxiDyn Incorporated (OxiDyn), a North Carolina based manufacturer of ozone based clean-in-place and sanitizing rinsing systems for the beverage and bottling industry. A preliminary acquisition agreement was executed in February 2001, subject to final negotiation, which calls for the Company to issue shares of common stock determined by dividing OxiDyn's net book value by the average closing price of the Company's common stock during the five-day trading period immediately prior to the closing date of the acquisition. The acquisition is pending, however, as of the date of this filing, and all indications are that the transaction will not close.

In November 2000, the Company loaned \$80,000 to OxiDyn to meet its current operating requirements, which is to be repaid upon the closing of the acquisition. In order to provide the above funding, the acquisition agreement called for the Company to complete a private placement of its common stock with an offering of at least \$300,000 at a price of \$0.19 per common share. This offering was to be purchased by OxiDyn's investors and shareholders. The Company received cash of \$190,000 related to the offering as of February 28, 2001. Subsequent to February 28, 2001 the Company received an additional \$100,000, the offering was closed, and 1,487,179 shares of common stock were issued. The Company advanced an additional \$120,386 in cash to OxiDyn subsequent to February 28, 2001 to OxiDyn to meet additional operating

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

requirements. As the completion of the acquisition is questionable, the Company wrote off the note receivable and other advances totaling \$200,386.

-13-

On June 15, 2001, the Company entered into an asset purchase and sale agreement with Paragon, LLC. The Principals of which are the employees of Cyclops Biochemical Corporation. The purchase price was \$285,000, which was established as the fair value for the Company, and approved by the board of directors. The Company received \$30,000 as a down payment and financed the balance of \$255,000 over five years, at 8% interest, secured by the Paragon's assets.

Consumers, food producers and processors, both large and small, are searching for new technologies to address food safety and sterilization concerns. Both consumers and food processors, who have relied heavily on chlorination and other chemicals to decontaminate foods and household items, are being forced to consider alternatives to chlorine and those other toxic chemicals. The Company believes that ozone products offer a lower cost and more environmentally-friendly and consumer accepted form of decontamination and sterilization than many other chemical treatments and irradiation. The FDA issued a final ruling allowing for the use of ozone in all food processing on June 28, 2001.

These statements are forward-looking and involve matters which are subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by such forward looking statements. These risks and uncertainties include product development or production difficulties or delays due to supply constraints, technical problems or other factors; technological changes; the effect of global, national and regional economic conditions; the impact of competitive products and pricing; changes in demand; increases in component prices or other costs; and a number of other risks including those identified by the Company throughout Form 10-KSB for February 28, 2001, and other risks identified from time to time in the Company's filings with the Securities and Exchange Commission, press releases and other communications. Information on the Procter & Gamble Agreements and the Acquisition of OxiDyn, Inc. can also be found in the Form 10-KSB for February 28, 2001. The Company assumes no obligation to update forward-looking statements.

Results of Operations

The Company's revenues were \$24,614 for the three months ended August 31, 2001 compared to \$6,321 for the three months ended August 31, 2000. The revenues were \$201,278 for the six months ended August 31, 2001 compared to \$82,408 for the six months ended August 31, 2000. This increase was due to the Company's efforts to generate more income and find institutions willing to pay for the Company's research efforts. The Company's gross margin for the three months ended August 31, 2001, was \$(36,223) compared to \$(67,611) for the three months ended August 31, 2000. The Company's gross margin for the six months ended August 31, 2001, was \$65,379 compared to \$(43,563) for the six months ended August 31, 2000. This increase is due to the increase in product sales as described above. The Company continues to closely monitor expenses to minimize all unnecessary operating costs. The Company expects to start receiving royalty payments from the sale of consumer products as described further in this section.

-14-

Research and development expenses decreased to \$17,772 and \$24,815 for the three and six months ended August 31, 2001 respectively from \$20,389 and \$33,845 for the three and six months ended August 31, 2000. This decrease is due the Company's reduced research and development activity and efforts to have strategic partners pay for the Company's research activities.

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Selling and marketing expenses increased to \$40,005 and \$78,161 for the three and six months ended August 31, 2001 respectively from \$35,985 and \$65,581 for the three and six months ended August 31, 2000. This increase is due to the Managements effort to produce an increase in sales.

General and administrative expenses increased to \$409,080 for the three months ended August 31, 2001 from \$201,041 for the three months ended August 31, 2000. General and administrative expenses increased to \$609,854 for the six months ended August 31, 2001 from \$443,725 for the six months ended August 31, 2000. The increase in general and administrative expenses for the three and six month period ended August 31, 2001 is primarily due to the write off of the note receivable and other advances to OxiDyn totaling \$200,386. Management is closely monitoring and controlling expenses. However legal and accounting expenses related to being a public company continue to escalate, and new accounting requirements and SEC regulations are being adopted with increasing regularity. These expenses while burdensome are crucial to providing and maintaining a market for the Company's securities. These expenses are expected to increase in fiscal 2002, with other potential increases due to management and human resource requirements for the Company should commercial activities increase, and more funds become available for this use.

Net income from discontinued operations related to the biochemical products business, which was sold subsequent to May 31, 2001, was \$16,076 and \$23,946 for the six months ended August 31, 2001 and 2000, respectively. The decrease in net income is due to continuous declining sales of biochemical products.

The Company recorded a net loss applicable to common stock for the three months ended August 31, 2001 of \$515,417. The loss recorded for the three months ended August 31, 2000 was \$368,916. The Company recorded a net loss applicable to common stock for the six months ended August 31, 2001 of \$659,737. The loss recorded for the six months ended August 31, 2000 was \$643,885.

Liquidity and Capital Resources

Cash used in operating activities was \$226,322 for the six months ended August 31, 2001 compared to \$804,108 for the six months ended August 31, 2000. This decrease is partly due to an increase in accounts payable and accrued liabilities and no common stock issued for services in fiscal 2002 compared to \$177,060 in fiscal 2001.

-15-

Net cash provided by financing activities for the six months ended August 31, 2001, was \$265,704 due to an additional \$100,000 received on a private placement offering related to the proposed acquisition of OxiDyn. The Company also received \$158,000 as of August 31, 2001 in connection with a private placement offering of approximately \$200,000 in convertible promissory notes at an annual interest rate of 10%. The note holders have the right to convert the principal amount into restricted common shares at the fair market value of the stock on the date of conversion. Approximately \$183,000 has been received from this private placement offering as of the date of this filing.

The Company had entered into a convertible secured loan for \$ 1,000,000 with Procter & Gamble that provided funds of \$250,000 in the fourth quarter of fiscal 2000 and \$750,000 in the second quarter of fiscal 2001. The loan accrued interest at 8% and is collateralized by a first security interest in all of the Company's Intellectual Properties and was due on or before February 28, 2001. The loan agreement granted a conversion right to Procter & Gamble allowing for the conversion of all or any part of the outstanding loan, including all or any part of interest due into shares in the Company's common

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

stock at anytime during the term of the loan, and at the sole discretion of Proctor & Gamble. The Company recognized its inability to repay the loan by the end of its third quarter, notified Proctor & Gamble, and negotiated a revised loan agreement. On February 4, 2001 the Company entered into a Conversion and Amendment Agreement with Proctor & Gamble that extended the due date for a portion of the loan amount equal to \$500,000 to February 28, 2002 and a conversion of the remaining \$500,000 loan principal into 500,000 shares of Series "E" convertible preferred stock, which occurred in March 2001.

Under the terms of the loan agreements, the Company is subject to various covenants, including maintaining minimum liquid assets in the form of cash or marketable securities of \$100,000. At February 28, 2001 and subsequent to that date, the Company is in default with the minimum liquid assets covenant and, therefore, the loan may be called at any time.

Total assets decreased to \$110,629 for the six months ended August 31, 2001 from \$315,234 for the year ended February 28, 2001, mainly due to a decrease related to the write off of the notes receivable from OxiDyn and the utilization of assets in operating activities. Total current liabilities decreased to \$1,164,747 at August 31, 2001 from \$1,354,288 at February 28, 2001, mainly due to the conversion of \$500,000 of notes payable to equity by Procter and Gamble, as described earlier in this section. This decrease was offset by additional notes payable of \$158,000 and increases in accounts payable and accrued liabilities resulting from ongoing operations of the Company.

The Company is attempting to generate more cash by way of financial assistance through collaborative partnering agreements, issuances of additional equity, debt arrangements, and product sales. Management believes that appropriate funding will be generated and future product sales will result from these opportunities and that the Company will continue operations over the next fiscal year; however, no assurances can be given that sales will be generated or that additional necessary funding will be raised. The Company anticipates it will receive limited royalties from some of its licensed products within fiscal year 2002 and expects the bulk of its revenues to stem from development

-16-

contracts and product sales. So far this fiscal year, as of August 31, 2001, the Company has negotiated and executed four separate development contracts with Kohler Co., Kaz, Inc., Nelson Laboratories, and ConAgra, with total current and future expected revenues under these contracts of approximately \$295,000. Subsequent to August 31, 2001 the Company has negotiated and begun a development contract with Pharmacia for \$30,000. These contracts involve the development of disinfection applications of the Company's ozone technology for consumer and industrial products.

Should the Company be unsuccessful in achieving the increased level of revenues and gross profits required to pay its operating expenses or in acquiring additional equity financing to pay the shortfall, the Company will seek direction from the Board of Directors as to what action would need to be taken.

Plan of Operation

The Company historically has acted as both the developer of its technologies and as the manufacturer and marketer of those technologies. It has become apparent that the customers within the markets pursued by the Company are intrigued by the performance and potential of the products and technologies. However, the size and operating capabilities of the Company does not support the confidence required for the Company's targeted customers to purchase the Company's products. The Company's targeted industrial customer base is accustomed to doing business with vendors and suppliers of a size and

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

stability that reasonably assures business continuity and internal product support. The single exception to this discrimination as to our limited size has been the United States Navy who is mandated to provide business opportunity for small business enterprises such as Cyclopps.

Under the Company's current plan of operations it will act as a limited manufacturer and marketer of its products and will also market its intellectual properties and development capabilities as a technology provider. Our efforts will be directed toward the creation of technology bridges and partnership and licensing arrangements with companies that provide products and services. The Company will utilize its technology to produce new complete ozone related processes and products. These anticipated ventures, partnerships and licensing arrangements are expected to include suppliers of equipment and appliances and suppliers of disposable or consumable products modified to utilize the Company's proprietary technologies under licensing and royalty agreements. The end result will create interlocking process systems that we believe will be both effective and economic. Additionally the process systems will be sold and serviced by vendors and suppliers already accepted by the target markets.

-17-

This model provides the manufacturers with technology and new product offerings and provides the Company with royalty revenue and commercialization of its technologies through already existing manufacturing, sales and service infrastructures.

The Company will continue to provide low volume production of ozone systems to customers like the United States Navy, and the Company also anticipates it will be compensated by one or more of the industry partners for design and development work required in modifying their existing products to accommodate the incorporation of the Company's proprietary technologies. This model allows the Company to keep the number of employees limited to specific requirements of the technology application, and converts the Company into a technology purveyor.

The Company's initial execution of a variation of this business model was illustrated by the relationship between the Company, Procter & Gamble and Otres, Inc. Cyclopps established a working relationship with Procter & Gamble early in 1999. In May of 1999, the Company was approached by the principals of Otres to assist in the development and validation of a toothbrush sanitizer and a kitchen sponge sanitizer utilizing ozone. The management of the Company determined the products could be of great interest to Procter & Gamble and, after having appropriate confidentiality documents executed, Otres agreed to allow the Company to introduce the product concepts to Procter & Gamble. Procter & Gamble determined they had products that would lend themselves to a co-marketing relationship with the Otres appliances as long as the product development was responsibly executed and the technology application proved safe and effective. Both Otres and Procter & Gamble engaged the Company for these activities. This resulted in the Company receiving revenues of approximately \$98,000 from both venture partners for the development and testing of the appliances. The Company continues to manage the relationship with Procter & Gamble for Otres under contract, and contributed to the execution of co-marketing agreements between Otres and CREST for the toothbrush sanitizer, and Otres and DAWN for dish washing soap that were announced at the International Home Appliance Show in Chicago on January 16, 2000. The Company negotiated to receive an ongoing royalty of approximately 3% from the sale of these appliances, which is expected to provide future revenues with minimal related costs incurred by the Company. Due to internal problems at Otres the products have yet to become fully commercialized. The revenue produced by the expected royalty stream has been minimal as of the filing date. The Company continues to assist Otres in solving its internal problems and positioning the products for success. In June, 2001 the FDA

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

granted its approval of the Otres Toothbrush Sanitizer.

A License and Royalty Agreement executed at year end 2001 with Consolidated Sills and Sterilizers of Boston, Mass. is also an illustration of the Company's new business plan. The agreement called for an up-front license fee and ongoing royalty, and includes revenues from the production of a prototype for Consolidated Stills and Sterilizers and for consulting fees for future work performed on the project. The FDA approval process facing Consolidated is formidable and the Company can make no prediction as to when the ozone sterilizer may be available to the Health-Care industry, but the financial burden is Consolidated's and the Company will receive a 3% royalty on any future gross sales of products utilizing our technology.

-19-

The plan provides for ongoing operating revenues derived from limited manufacturing and direct sales of the companies' industrial products, ongoing contract product development, with the future revenues derived primarily through license and royalty streams generated by the success of its selected strategic partners in commercializing the products.

The Company anticipates its revenues as well as the source of those revenues to change significantly through establishment of these types of relationships. However, there can be no assurance that the current loan to Procter & Gamble can be serviced upon its due date nor can there be any assurance that any of the Company's products will be accepted in such numbers that will generate adequate revenues and cash flow sufficient to cover the ongoing costs of operation.

On March 13, 2001 the Company was granted a very broad patent by the United States Patent office relating to the use of water, ozone and food grade surfactants for use in all food processing activities. The patent is extremely important to the Company's ability to defend a position of proprietary processes for development and subsequent licensing since an FDA ruling was granted on June 28, 2001, that allows the use of ozone in the processing of certain food items. The Company is in an enviable position and expects a resurgence of the interest previously expressed by potential strategic partners in the food processing sector.

The Company continues to seek customers and strategic partners such as, Kohler Co., Kaz, Inc., and Nelson Laboratories, who are sufficiently convinced of the potential to collaboratively participate in necessary research and development costs. These customers and strategic partners not only may provide revenues from research and development contracts but also follow-on royalty revenues from the purchase of systems and processes.

The Company has provided major agricultural producers with prototype ECO-PURE test systems that have been installed in wet produce processing plants, long-term produce storage facilities, short term banana and tomato ripening rooms, and for use in treatment of herbal remedies and dietary supplements. The Company will seek to commercialize these successful test processes based on the new FDA ruling discussed above.

Even with sufficient funds available, the ongoing challenge facing the Company is that of educating potential partners, government, industry and the end consumer about the benefits of ozone. Ozone is a naturally occurring phenomenon that is usually associated with photochemical smog or an eroding level of protection in our atmosphere. It is the Company's intent to provide this education and show the beneficial side of ozone decontamination. For industry, ozone is a cost competitive and environmentally friendly answer to microbial contaminants. For the consumer, ozone kills harmful microorganisms quickly and leaves behind no chemical residue.

-19-

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

The information set forth herein as to anticipated research and development costs, equipment purchases and increase in employees are management's best estimates based upon current plans. Actual expenditures may be greater or less than such estimates depending on many factors including, but not limited to, the availability of new technologies, the completion or lack of completion of certain strategic alliances, and the timing and successful completion of the Company's stated requirement to acquire additional operating and growth capital, industry initiatives, success of the Company's research and development efforts, and other factors.

-20-

>From time to time, the Company may publish forward-looking statements relating to such matters as anticipated financial performance, business prospects, technological developments, new products, research and development activities and similar matters. The private Securities litigation Reform Act of 1995 provides a safe harbor for forward looking statements. In order to comply with the terms of the safe harbor, the Company notes that a variety of factors could cause the Company's actual results and experience to differ materially from the anticipated results or other expectations expressed in the Company's forward looking statements. The risks and uncertainties that may affect the operations, performance, development and results of the Company's business include, but are not limited to, the following:

1. Market acceptance of the Company's products;
2. Obtaining sufficient additional operating capital in the form of debt or equity;
3. The existence of an orderly market in the Company's securities;
4. Increased sales of the various products of the Company;
5. Continued success in the Company's research and development activities; and
6. Successful completion of strategic alliances

PART II - OTHER INFORMATION

Item 1. Legal Proceedings. None.

Item 2. Changes in Securities and Use of Proceeds None.

Item 3. Defaults Upon Senior Securities. See discussion on page 12, Note 5 to the Condensed Consolidated Financial Statements included herein and page 16 "Liquidity and Capital Resources," with respect to the discussion concerning the default on the loan convents of the Proctor and Gamble Senior Secured note.

Item 4. Submission of Matters to a Vote of Security Holders. None.

Item 5. Other Information. None

Item 6 Exhibits and Reports on Form 8-K and S-8. None

-21-

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, as amended, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CYCLO3PSS CORPORATION

Edgar Filing: CYCLO3PSS CORP - Form 10QSB

Date: October 15, 2001

By/s/ William R. Stoddard
William R. Stoddard
Chief Executive Officer
Principal Executive Officer

Date: October 15, 2001

By/s/ Mondis Nkoy
Mondis Nkoy
Controller, Corporate Secretary
Principal Financial Officer

-22-